Lataa...
Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B
Although the desire to develop gene therapy for hemophilia B is high, safety remains a concern. Therefore, improving the therapeutic index of gene therapy vectors is an important goal. Thus, we evaluated the use of three bioengineered factor IX (FIX) variants with improved catalytic activity in the...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Mary Ann Liebert, Inc.
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2861950/ https://ncbi.nlm.nih.gov/pubmed/19196177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2008.084 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|